
Oncology NEWS International
- Oncology NEWS International Vol 4 No 7
- Volume 4
- Issue 7
Zeneca Files NDA for Arimidex
WILMINGTON, Del--Zeneca Pharmaceuticals has filed a new drug application (NDA) for the use of Arimidex (anastrozole) tablets for the treatment of advanced breast cancer in postmenopausal women who have progressed following therapy with tamoxifen (Nolvadex).
WILMINGTON, Del--Zeneca Pharmaceuticals has filed a new drug application(NDA) for the use of Arimidex (anastrozole) tablets for the treatmentof advanced breast cancer in postmenopausal women who have progressedfollowing therapy with tamoxifen (Nolvadex).
Arimidex, a nonsteroidal compound, is one of the first of a newclass of selective oral aromatase inhibitors, designed to reducethe production of estrogen. The NDA is based on randomized, controlledtrials involving 764 women with advanced breast cancer, the companysaid.
Articles in this issue
almost 31 years ago
ODAC Recommends Accelerated FDA Approval of Ethyol for Cytoprotectionalmost 31 years ago
House Panel Holds Hearing on Self-Referralalmost 31 years ago
Health-Related Legislationalmost 31 years ago
Mitoguazone Appears Promising in HIV-Associated Refractory NHLalmost 31 years ago
Responses to Anti-HER2 MoAb Seenalmost 31 years ago
NCI Committed to Increasing Minority Participation in Clinical Trialsalmost 31 years ago
MoAb May Improve Detection of Colon And Rectal Canceralmost 31 years ago
Cord Blood is Used as Source of Stem Cells for Pediatric Transplantationalmost 31 years ago
HCFA Needs to Do More to Prevent Medicare/Medicaid Fraud and AbuseNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.


























































